Peking University Cancer Hospital & Institute: Carcinoma, Non-Small-Cell Lung trials

The registry lists 21 Carcinoma, Non-Small-Cell Lung studies with Peking University Cancer Hospital & Institute as lead sponsor. 13 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 13No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical StudyNot yet recruitingNCT07894367Phase 2
• Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide ProbesRecruitingNCT07848243Phase 2
• Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLCNot yet recruitingNCT07567326Phase 2
• PD-L1 Targeting Peptide Probe for PET Imaging of Solid TumorNot yet recruitingNCT07442292
• Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mgNot yet recruitingNCT07298148Phase 2
• High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLCNot yet recruitingNCT07182708Phase 2
• A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCRecruitingNCT06969612Phase 1
• Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLCRecruitingNCT06849167Phase 2
• Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRDNot yet recruitingNCT06780839Phase 2
• Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLCNot yet recruitingNCT06690541
• Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung LesionsRecruitingNCT06648317
• Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung CancerRecruitingNCT06081777
• A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerRecruitingNCT05104788Phase 2
• Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC PatientsCompletedNCT05758116Phase 2
• A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung CancerStatus unknownNCT05380024Phase 2
• Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung CancerStatus unknownNCT05132218
• Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLCStatus unknownNCT04629027
• A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.Status unknownNCT04606303Phase 2
• Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLCStatus unknownNCT04303130Phase 2
• Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung CancerStatus unknownNCT04137588
• A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLCStatus unknownNCT04023617Phase 2